Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake

NARecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
GlucocorticoidsOverweight and ObesityOvereating
Interventions
DRUG

Metyrapone And Hydrocortisone

"Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7"

DRUG

Placebo

"Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7"

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

Eleonora Seelig

OTHER